About Our Global Health Access Initiative
We're dedicated to making the world a better place, which is why we launched our Global Health Access Initiative in 2015. This initiative aims to combat HIV/AIDS and related coinfections, including HIV-associated malignancies such as leukemias and rare lymphomas, in low- and middle-income countries (LMICs).
Our mission is to help maximize equitable global health access through shared value investment in LMICs. We work with numerous like-minded partners, including non-governmental organizations (NGOs), academic institutions, international organizations, policy organizations and the Ministry of Health.
Leveraging our position as a leader in biomedical life sciences, we’ve collaborated with global healthcare leaders to develop breakthrough HIV monitoring solutions that contribute directly to the treatment process for patients suspected of having advanced HIV disease and hematological malignancies.
We support charitable donations and small research grants that align with our shared values and strategic interests:
- HIV CD4 Testing
- Immunophenotyping for leukemia and lymphoma
- Immune disorders
- Cell and gene therapies
- Innovations for early detection screening (e.g., the ClearLLab LS system, Implementation Science, etc.)
Our shared initiatives are driven by a commitment to health equity and improving access to essential testing, supporting the fight against HIV/AIDS and cancer.
Since 2015, we have:
- Pioneered flow cytometry diagnostic testing technology for HIV/AIDS (starting in the 1980s)
- Provided more than 50 million HIV tests
- Provided over 3,500 oncology tests for hematologic malignancies
- Introduced CD4 count testing for use in labs that lack access to flow cytometry technology
- Donated nearly $500,000 in financial support to various community organizations, academic institutions, and National Health Laboratory Service in East Africa
- Offered the only World Health Organization-approved, automated, high-throughput CD4 testing solutions for centralized laboratories in high-burden HIV settings
